Phase I Trial of Sorafenib Maintenance Therapy for Patients With FLT3-ITD AML After Allogeneic Stem Cell Transplantation
Phase of Trial: Phase I
Latest Information Update: 24 Mar 2017
At a glance
- Drugs Sorafenib (Primary)
- Indications Acute myeloid leukaemia; Graft-versus-host disease
- Focus Adverse reactions
- 03 Oct 2016 Status changed from active, no longer recruiting to completed.
- 17 Dec 2012 Planned end date changed from 1 Aug 2014 to 1 Aug 2016 as reported by ClinicalTrials.gov.
- 24 Aug 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.